In this work, we demonstrate that PD-L1 is a substrate of NEK2, and combinatorial inhibition of NEK2 and PD-L1 largely improves the therapeutic efficacy of pancreatic cancer in preclinical models. This evidence concerns the gene NEK2 and pancreatic neoplasm.